Pain Therapeutics, Durect jump as Pfizer to continue Remoxy development

Pain Therapeutics (PTIE) and Durect (DRRX) get a bit of good news as Pfizer (PFE) will continue to develop Remoxy.

According to PTIE, PFE will proceed with the additional clinical studies and other actions required to address the CRL."

Deal economics are unchanged: $15M to PTIE upon approval, 15% of the first $1B in net sales to PTIE (the rate goes to 20% of U.S. net sales after that), ex-U.S. royalty rate is 10%. Supplemental payment of 6-11.5% of net sales is also due to PTIE and is "tied to ... financial obligations to" DRRX. (PR)

Interestingly, both PTIE and DRRX spiked on October 17, seemingly without explanation.

PTIE +25% premarket, DRRX +13%

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs